OCT 25, 2017 6:00 AM PDT

WEBINAR #3: Enabling neurological disease research via DNA fragment analysis on the new SeqStudio genetic analyzer

Sponsored by: Thermo Fisher Scientific
Speaker
  • Senior Vice President, Research and Development, Asuragen
    Biography
      Dr. Gary Latham is Senior Vice President of R&D for Asuragen, a molecular diagnostics company focused on genetics and oncology. Gary joined Asuragen when it was founded in 2006, and currently oversees the company's research, assay development, partnered R&D, and bioinformatic teams. He guided the development of AmplideX® PCR technology for fragile X syndrome and other DNA repeat disorders, and DNA- and RNA-based QuantideX® NGS products for oncology applications. Gary is an inventor on 12 issued US patents, has received >$13M in research grants from the NIH and the Cancer Prevention and Research Institute of Texas (CPRIT), and has authored >40 peer-reviewed publications.

    Abstract

    DATE: October 25, 2017
    TIME: 06:00am PDT, 09:00am EDT

    This is the third topic in the webinar series on ‘Sanger Sequencing & Fragment Analysis made easy’.

    Repetitive DNA sequences comprise half of the human genome and include at least 1.6 million short tandem repeats with dark functions and unknown disease implications. Recent genome-wide studies have illuminated thousands of associations of such repeat elements with changes in gene expression. In addition, over 30 Mendelian disorders are known to be caused by triplet repeat expansions. Thus there is a rapidly growing appreciation that repetitive “dark” DNA is discoverable, discernible and diagnostic.

    In this webinar, we will discuss:

    • How reliable, long-read AmplideX® PCR technology can be combined with the SeqStudio Genetic Analyzer to operationalize the routine detection of established and emerging repeat DNA markers in an easy-to-use assay system
    • Data showing sensitive and accurate analyses of GC- and AT-rich repeat expansions and length polymorphisms associated with Fragile X Syndrome, ALS/FTD, Myotonic Dystrophy, Huntington’s Disease, and Alzheimer Disease
    • The implications of high-resolution repeat DNA genotyping for scientific and clinical research of neurodevelopmental, neurodegenerative, and neuromuscular disorders

    Other topics in the webinar series:


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    Loading Comments...
    Show Resources
    Attendees
    • See more